Skip to content
Tilos Therapeutics logo — Developing innovative antibody therapeutics to target crucia...

Tilos Therapeutics

Developing innovative antibody therapeutics to target crucial immunological pathways with a focus on regulatory T cells and effector cell regulation.

Founded 2016 Venture round Total: $3.80M Biotechnology, Health and Wellness +1

General Information

Company Name Tilos Therapeutics
Founded Year 2016
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Tilos Therapeutics. To contact Tilos Therapeutics, visit tilostherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tilos Therapeutics compare?

A PDF of Tilos Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tilos Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Tilos Therapeutics

Tilos Therapeutics is a biotechnology and pharmaceutical startup that focuses on developing innovative antibody therapeutics targeting crucial immunological pathways, with a specific emphasis on regulatory T cells and effector cell regulation. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company's initial research is centered around antibodies specific to Latency Associated Peptide of TGF beta. In September 2017, Tilos Therapeutics secured a $3.05M Venture Round investment, with ShangPharma being the lead investor in this round.

Business keywords: biopharmaceuticals, antibody therapeutics, immunological pathways, regulatory T cells, effector cell regulation, Latency Associated Peptide, TGF beta, biotech startup, Cambridge, Massachusetts

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $3.05M 1
ShangPharma
21 Sep 2017
Seed Round $750.00K -
30 Aug 2016

Tilos Therapeutics Alternatives & Competitors

View All Alternatives
Tilos Therapeutics vs

HI-Bio is a clinical-stage biotech company delivering targeted therapies for patients with immune-me...

Acquired
22 employees
Biotechnology, Health and Wellness
Tilos Therapeutics vs

Pioneering advancements for celiac disease through innovative diagnostics and therapeutic solutions

Venture round
Biotechnology, Health Care
Tilos Therapeutics vs
Zebra Biologics
Zebra Biologics United States

Zebra Biologics is a Biotechnology company located in 1041 Old Marlboro Road, Concord, MA, United St...

Venture round
2 employees
Biotechnology, Health Care

FAQ About Tilos Therapeutics

Developing innovative antibody therapeutics to target crucial immunological pathways with a focus on regulatory T cells and effector cell regulation.
Tilos Therapeutics was founded in 2016.
Tilos Therapeutics operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceuticals, antibody therapeutics, immunological pathways and regulatory T cells.
Tilos Therapeutics has completed 2 funding rounds, raising a total of $3.80M. The latest funding stage is Venture round.
Top alternatives and competitors to Tilos Therapeutics include HI-Bio: A Biogen Company, ImmusanT, Zebra Biologics, Garuda Therapeutics, i2o Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tilos Therapeutics and HI-Bio: A Biogen Company are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tilos Therapeutics, https://bouncewatch.com/company/tilos-therapeutics, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout